Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination** of two agents: hyodeoxycholic acid, a secondary bile acid, and a statin, which refers to any drug from the statin class (HMG-CoA reductase inhibitors). Hyodeoxycholic acid is used occasionally for its choleretic and hepatoprotective properties, whereas statins are widely prescribed to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, thereby reducing synthesis of cholesterol in the liver. Although combination therapy of **bile acids** (usually ursodeoxycholic acid, not hyodeoxycholic acid) and statins has been studied for hypercholesterolemia, synergistic lipid-lowering effects and potential hepatoprotective effects have been mostly described for ursodeoxycholic acid + statin, not specifically for hyodeoxycholic acid. No specific products or approved drugs containing hyodeoxycholic acid + statin are documented in main drug databases, and no routine use of this specific combination is established clinically.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyodeoxycholic acid + statin.